



**2023 Oncology Fellows Program:
New Horizons in Quality Cancer Care™**

An Exploration of Oncology Professions Beyond Research and Clinical Practice



Moderator: Crystal S. Denlinger, MD

Panelists:

Jonathan D. Cheng, MD

Robert Coleman, MD

Yehoda M. Martei, MD, MSCE

Barbara L. McAneny, MD



Crystal S. Denlinger, MD,

Senior Vice President, Chief Scientific Officer, *National Comprehensive Cancer Network*

Crystal S. Denlinger, MD, is Senior Vice President, Chief Scientific Officer at the National Comprehensive Cancer Network (NCCN). As a member of NCCN's Senior Leadership Team, Dr. Denlinger helps steer strategic direction for the organization. She also oversees the NCCN Oncology Research Program, provides input into NCCN's Clinical Information Operations through oversight of the Drugs & Biologics and Biomarkers Compendia, and supports the planning and execution of NCCN's continuing education activities.

Dr. Denlinger earned her medical degree from the New Jersey Medical School, University of Medicine and Dentistry of New Jersey. She completed an internal medicine categorical residency at Mount Sinai Medical Center and a hematology/oncology fellowship at Fox Chase Cancer Center and Temple University Hospital. Prior to joining NCCN, Dr. Denlinger held several leadership positions with Fox Chase Cancer Center—an NCCN Member Institution—including Chief, Gastrointestinal Medical Oncology, Deputy Director of the Early Drug Development Phase 1 Program, Director of the Survivorship Program, and Associate Professor in the Department of Hematology/Oncology. She continues to see patients at Fox Chase Cancer Center in a limited, volunteer capacity.

Dr. Denlinger has been involved with NCCN for many years. She contributed to the development of several NCCN Guidelines, including serving as Chair of the NCCN Survivorship Panel and as a member of the NCCN Esophageal/Gastric Cancers Panel. She also served on the editorial board for *JNCCN—Journal of the National Comprehensive Cancer Network* and on multiple committees for the NCCN Oncology Research Program. She is a past-recipient of the NCCN Foundation's Young Investigator Award, as well as the NCCN Rodger Winn Award for her leadership, drive, and commitment in service to developing clinical practice guidelines.



Jonathan D. Cheng, MD

Senior Vice President; Therapeutic Area Head of Oncology Drug Development, *Bristol Myers Squibb*
Attending Physician; Associate Professor, *Fox Chase Cancer Center*

Jonathan D. Cheng, MD, is Senior Vice President of Clinical Oncology Therapeutic Area Head at Bristol Myers Squibb (BMS) and an Attending Physician and Associate Professor at Fox Chase Cancer Center. He previously held several positions at Merck, including Vice President Clinical Research in Late-Stage Oncology, Associate Vice President of Aerodigestive and Hematologic Malignancies, Executive Director of the Product Development Team Lead of Head/Neck Cancers, and Clinical Director of multiple early and late-stage clinical trials.

Dr. Cheng received his medical degree at the University of Minnesota Medical School, where he also completed a residency in internal medicine. He later completed medical oncology and gastrointestinal oncology fellowships at Roswell Park Cancer Institutes and a laboratory research fellowship at Fox Chase Cancer Center.

Dr. Cheng's clinical practice focuses on the diagnosis, treatment, and prevention of gastrointestinal malignancies, including colorectal, esophageal, pancreatic, stomach, and liver, gall bladder, and bile duct cancer. He is well-versed in the multitude of complex medical, emotional, and social issues faced by patients with these cancers. He uses this experience to guide patients through the range of therapeutic options, including the latest research findings and newest clinical trials.

In his current role at BMS, Dr. Cheng is responsible for the clinical development of novel therapeutics of the BMS oncology pipeline and leads a dedicated group of more than 50 oncology physicians and more than 150 clinical scientists. His translational research focuses on the importance of stroma that tumors utilize to grow and metastasize. He has served as the Principal Investigator of numerous cooperative group tumor microenvironment trials investigating new agents in colorectal, pancreas, esophageal, and gastric cancers. He also has authored and led multiple registration-enabling clinical trials and led the health authority submission and approvals for more than a dozen oncology indication across multiple compounds, including pembrolizumab and lenvatinib. Additionally, he has led dozens of Health Authority interactions globally including pre-supplemental biologics.

Dr. Cheng is actively involved in a number of professional organizations, including the American Society of Clinical Oncology. He also has held a number of leadership positions for the Food & Drug Administration (FDA), including Industry Representative of the FDA's Oncology Drug Advisory Committee, Therapeutic Area Supervisor and Representative for the FDA's License Application meetings, and member of the FDA Oncology Drug Advisory Committee. He also has held positions with the Oral Explanation of European Medicines Agency (EMA), the EMA Scientific Advisory Group for Oncology, and the EMA Scientific Advice Committee.



Robert Coleman, MD

Chief Medical Officer, *Sarah Cannon Research Institute (SCRI), The US Oncology Network*

Robert L Coleman, MD, is a gynecologic oncologist and Chief Scientific Officer at US Oncology Research.

Dr. Coleman received his medical degree from Creighton University in Omaha, Nebraska. He then completed a residency in obstetrics and gynecology at the Northwestern Medicine Prentice Women's Hospital in Chicago, Illinois and a fellowship in gynecologic oncology at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas.

In his current role, Dr. Coleman is the senior-most clinician scientist on the US Oncology Network Leadership Team and manages the clinical trials oncology portfolio for US Oncology Research. He has a broad set of responsibilities focused on expanding the organization's research efforts and strengthening the culture of research across the Network. He works collaboratively with the Network and McKesson Leadership Teams in addition to manufacturers, laboratory and device companies, and physicians within the Network. Through these collaborations, Dr. Coleman develops and maintains the infrastructure needed for Network physicians to access and participate in research, enabling them to incorporate more novel therapies into their patients' treatment plans. His role also includes evaluating emerging technologies, digital platforms, and artificial intelligence strategies in order to accelerate research within the Network.

Dr. Coleman is an internationally recognized leader in gynecologic cancer research. His research interests include drug discovery and novel therapeutics for ovarian, uterine, cervical cancer, clinical trial development, and statistical design. He has extensive expertise in creating and managing research programs in various care delivery settings, and he has been instrumental in developing many of the promising treatments now available for gynecological cancer management. He has served as Principal Investigator (PI) or co-PI for several CTEP-funded and industry-supported prospective clinical trials and has authored or co-authored over 700 scientific publications, including over 360 peer-reviewed original research articles. He also has contributed to many book chapters and has edited and written six books.

Among his career highlights, Dr. Coleman pioneered numerous innovative surgical techniques for ovarian cancer management, led multiple clinical trials resulting in breakthrough therapies for the treatment of ovarian cancer, and mentored new generations of oncologic researchers and established new training techniques. Prior to his current role, Dr. Coleman served as a Professor and the Ann Rife Cox Chair of the Department of Gynecologic Oncology and Reproductive Medicine MDACC, where he also served as Executive Director of Cancer Network Research. He also serves as Co-Director of the Gynecologic Oncology Group (GOG) Partners Foundation, Inc. He is the immediate Past-President of both the International Gynecologic Cancer Society and the former President of the Society of Oncologic Gynecology (SGO). He has received a number of awards throughout his career in recognition of his accomplishments in teaching and research, including the APGO/CREOG award in teaching and the 2023 SGO's Innovator in Cancer Research Award.



Yehoda M. Martei, MD, MSCE

Vice Chief of Diversity, Inclusion and Health Equity
Assistant Professor of Medicine, Hematology - Oncology Division
Global Health Scholar, *Penn Center for Global Health, Perelman School of Medicine
University of Pennsylvania , Abramson Cancer Center at the University of Pennsylvania*

Yehoda M. Martei, MD, MSCE, is Vice Chief of Diversity, Inclusion, and Health Equity at the Perelman School of Medicine at the University of Pennsylvania, an Assistant Professor of Medicine in the Division of Hematology – Oncology, and a Global Health Scholar in the Penn Center for Global Health. She is also an Attending Physician at the University's Abramson Cancer Center.

Dr. Martei received her medical degree from Yale University School of Medicine. She completed her residency at the University of California, San Francisco (UCSF) Medical Center, and Hematology - Oncology fellowship at the Hospital of the University of Pennsylvania, where she also received a master's of science degree in clinical epidemiology. She is board-certified in internal medicine with a subspecialty in medical oncology.

Dr. Martei specializes in breast cancer and global health. Her research goals are to improve access to cancer therapy in low-income countries and low-resource communities and improve outcomes in breast cancer patients, including people living with HIV in sub-Saharan Africa, using implementation science.

Dr. Martei's current projects include evaluation of access to WHO essential cancer medicines and their impact on suboptimal cancer therapy delivery. She is a recipient of a Fogarty International Center K01 career development award to study the adaptation and fidelity of breast cancer guidelines in Botswana.

Dr. Martei has worked with prominent oncology organizations to improve and advance cancer care globally. Among these efforts, she serves as a technical consultant for the WHO Breast Cancer Initiative and a technical consultant on the task team for the Access to Oncology Medicines Consortium led by the Union for International Cancer Control. She also worked with the WHO Steering Committee and the Union for International Cancer Control Task Team to update the 2017 Model List of Essential Medicines for Cancer.



Barbara L. McAneny, MD

Chief Executive Officer, *New Mexico Cancer Center/NMOHC*
New Mexico Oncology Hematology Consultants, Ltd.
Former President, *American Medical Association*

Barbara L. McAneny, MD, is the Chief Executive Officer of the New Mexico Cancer Center/New Mexico Oncology Hematology Consultants, Ltd. (NMOHC) and a former President of the American Medical Association (AMA).

Dr. McAneny graduated *magna cum laude* from the University of Minnesota and with honors from the University of Iowa College of Medicine. She completed her residency in internal medicine at the University of Iowa and her fellowship in hematology/oncology at the University of New Mexico.

Dr. McAneny is a practicing medical oncologist/hematologist and co-founder of NMOHC with Clark Haskins, MD. As a managing partner of the practice, she built the New Mexico Cancer Center as the first physician-owned, multi-disciplinary cancer center in the state with clinics in two locations. She also founded the New Mexico Cancer Center Foundation, which provides grants to help patients with nonmedical expenses. Additionally, Dr. McAneny is one of the founders and current Chair of the Board of the National Cancer Care Alliance, a group of independent practices collaborating to use innovation to deliver high-quality, high-value cancer care and to develop new alternative payment models based on sound data-driven principles. Prior to this, she was a founding member of Oncology Circle, a group of oncology practices using data to promote best practices.

Dr. McAneny's interest in using data to improve practice sustainability began when she was appointed to the Centers for Medicare & Medicaid Service's Practicing Physicians Advisory Council. Later, she received a \$19.8 million grant from the Centers for Medicare & Medicaid Innovation to demonstrate how oncology practices could use triage pathways to dramatically lower costs while improving outcomes. This award, named *COME HOME* (for Community Oncology Medical Home), later was incorporated into Medicare's Oncology Care Model.

Dr. McAneny has long-standing history of leadership involvement in local and national professional organizations. She is a Fellow and former member of the Board of Directors of the American Society of Clinical Oncology (ASCO), a Master of the American College of Physicians, and Past-President of several organizations, including the New Mexico Medical Society (NMMS), the Greater Albuquerque Medical Association, and the New Mexico chapter of the American College of Physicians. Additionally, she serves as a member of the Community Oncology Alliance Board of Trustees and on the Board of Directors of the Cancer Center Business Summit.

Dr. McAneny's involvement the AMA evolved over a number of years. She became ASCO's delegate to the AMA in 2002 and was elected to the AMA Council on Medical Service a year later, serving as its Chair from 2009 to 2010. She has been a member of the AMA Board of Trustees since June 2010, serving as its Chair from 2015 to 2016, and became the 173rd President of the AMA in June 2018.

Among other volunteer activities, Dr. McAneny has served on the governor of New Mexico's Task Force on Prenatal Care, the Board of Planned Parenthood of New Mexico, and as Chair of the Joint Task Force of the NMMS and the New Mexico Bar Association on domestic violence. She also has received a number of awards throughout her career, including New Mexico's *Woman on the Move Award* and *Woman of Influence Award*, as well as *Albuquerque The Magazine's* "Top Doc" Award.



National Comprehensive Cancer Network®

NCCN Member Institutions

- **Who We Are**


An alliance of leading cancer centers devoted to patient care, research, and education

- **Our Mission**

To improve and facilitate quality, effective, equitable, and accessible cancer care so all patients can live better lives

- **Our Vision**

To define and advance high-quality, high-value, patient-centered cancer care globally



[NCCN.org](https://www.nccn.org) – For Clinicians

[NCCN.org/patients](https://www.nccn.org/patients) – For Patients

[Education.nccn.org](https://www.education.nccn.org) – CE Portal